WHO ICTRP trial
A 12-week, randomized, double-blind, placebo-controlled, parallel group…
EUCTR2004-002894-21-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2004-002894-21-GB |
|---|---|
| Public title | A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to 15 mg o.d.) in patients aged = 65 years with overactive bladder - Not applicable |
| Scientific title | A 12-week, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the efficacy, safety and tolerability of darifenacin (7.5 mg o.d. with voluntary up-titration to 15 mg o.d.) in patients aged = 65 years with overactive bladder - Not applicable |
| Primary sponsor | Novartis Pharma Services AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Hungary;Germany;United Kingdom;Sweden |
| Conditions | Overactive bladder (OAB) |
| Interventions | Trade Name: EMSELEX 7.5 prolonged-release tablets Product Name: EMSELEX 7.5 mg Product Code: DAR328A Pharmaceutical Form: Prolonged-release tablet Pharmaceutical form of the placebo: Prolonged-release tablet Route of administration of the… |
| Registration date | Mar 16, 2005 |
| Target size | 399 |
| Secondary IDs | CDAR328A2409 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: